Neogen raises guidance: Neogen stock loses 4.03 percent

Published on 10/08/2026 at 15:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal first-quarter 2027 revenue reached USD 222.80 million, up 6.50 percent. Neogen stock costs EUR 9.99 on October 8, 2026 versus EUR 10.41.

NEOG, US6404911066, Illustration mit AI erstellt.

Neogen Corporation (US6404911066) was trading at EUR 9.99 at Lang & Schwarz on October 8, 2026 at 3:38 p.m. CEST, down 4.03 percent from the EUR 10.41 prior close. The company had raised its fiscal 2027 revenue and Adjusted EBITDA guidance on October 6, 2026, while its latest quarter showed higher revenue but a GAAP net loss, according to Neogen Corporation.

What does the guidance raise change?

For fiscal 2027, Neogen lifted revenue guidance from USD 880.00 million to USD 885.00 million to USD 890.00 million. Adjusted EBITDA guidance rose from USD 180.00 million to USD 182.00 million to USD 181.00 million to USD 183.00 million, giving investors a clearer operating benchmark for the year.

In the fiscal first quarter ended August 31, 2026, revenue was USD 222.80 million, compared with USD 209.20 million a year earlier, a 6.50 percent increase. Adjusted EBITDA reached USD 41.60 million versus USD 35.50 million, while Adjusted EBITDA margin improved to 18.70 percent from 17.00 percent, according to Neogen Corporation.

Three dated signals for Neogen

On September 30, 2026, Guggenheim maintained a Buy rating and raised its price target from USD 12.00 to USD 14.00, as reported by Ticker Nerd. On October 6, 2026, Neogen reported fiscal first-quarter revenue of USD 222.80 million and Adjusted EPS of USD 0.08, compared with USD 0.04 a year earlier, according to Neogen Corporation. On October 6, 2026, the company also announced a strategic collaboration and equity investment in Hinalea Imaging Corp. for digital food safety imaging, as reported by finanzen.ch.

Upcoming operational milestones

Neogen expects its multi-quarter Petrifilm manufacturing transition to begin in November 2026. Regulatory reviews connected with the planned Genomics business sale to Zoetis are expected to conclude by the end of December 2026, according to Neogen Corporation.

Stock remains below its yearly high

The Lang & Schwarz price of EUR 9.99 on October 8, 2026 at 3:38 p.m. CEST was down 4.03 percent versus the EUR 10.41 prior close. The primary Nasdaq listing had a USD 5.37 to USD 14.26 52-week range and a market capitalization of USD 2.5 billion as of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Neogen stock.